Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Down 23.3% in September

Barinthus Biotherapeutics plc (NASDAQ:BRNS) was the recipient of a significant decline in short interest during the month of September. As of September 30th, there was short interest totalling 4,600 shares, a decline of 23.3% from the September 15th total of 6,000 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 26,800 shares, the short-interest ratio is currently 0.2 days.

Barinthus Biotherapeutics Trading Down 1.7 %

Shares of BRNS stock traded down $0.02 during trading on Friday, hitting $1.17. The company’s stock had a trading volume of 5,993 shares, compared to its average volume of 39,316. The business has a fifty day moving average of $1.26 and a 200-day moving average of $1.77. The company has a market cap of $46.12 million, a PE ratio of -0.71 and a beta of -0.53. Barinthus Biotherapeutics has a 52 week low of $1.11 and a 52 week high of $5.10.

Barinthus Biotherapeutics (NASDAQ:BRNS) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.01). As a group, research analysts predict that Barinthus Biotherapeutics will post -1.71 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on BRNS. Alliance Global Partners cut their price objective on shares of Barinthus Biotherapeutics from $11.00 to $9.50 and set a “buy” rating for the company in a report on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Barinthus Biotherapeutics in a research report on Thursday, September 26th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. M&G Plc purchased a new stake in shares of Barinthus Biotherapeutics during the second quarter worth about $7,276,000. Alphabet Inc. bought a new stake in Barinthus Biotherapeutics during the 2nd quarter valued at about $2,119,000. DC Funds LP purchased a new position in Barinthus Biotherapeutics in the 1st quarter worth approximately $1,528,000. BlueCrest Capital Management Ltd bought a new position in shares of Barinthus Biotherapeutics during the first quarter valued at $1,292,000. Finally, Ipswich Investment Management Co. Inc. purchased a new stake in shares of Barinthus Biotherapeutics during the 2nd quarter valued at about $32,000. Hedge funds and other institutional investors own 25.20% of the company’s stock.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.